register

News & Trends - Pharmaceuticals

New Pharmacy Practice Review on opioids aims to reduce harms from long term use

Health Industry Hub | September 25, 2019 |

Opioids can be an effective component of the management of acute and cancer-related pain. However, there is little empirical evidence supporting the use of opioids in chronic non-cancer pain. Not only do opioids pose significant risk of harms, most studies of patients with chronic non-cancer pain have failed to demonstrate improvement in pain or functioning with long-term opioid use.

A new national education program from NPS MedicineWise, Opioids, chronic pain and the bigger picture, aims to equip health professionals with tools and resources to reduce the harms of opioids while ensuring adequate pain management and quality of life for patients with chronic non-cancer pain. NPS MedicineWise educational visitors will undertake one-on-one and small group visits in general practice around Australia, and the program will also provide resources to empower consumers make more informed decisions about opioids.

NPS MedicineWise CEO and pharmacist Adj A/Prof Steve Morris says pharmacists can be among the first to get involved in the new program by participating in a Pharmacy Practice Review, Opioids: reducing harms from long term use, available from this week.

“This Pharmacy Practice Review focuses on the important role pharmacists play to ensure the safe use of opioids for chronic non-cancer pain and to identify patients who may be at risk of harm from long-term use,” said Mr Morris.

“I strongly encourage pharmacists to upskill in this important area to help support quality use of opioids for their patients.”

Enhance visibility, amplify brand value and share your expertise with our Pharma, Biotech and MedTech subscribers. Contact us.

This Pharmacy Practice Review provides pharmacists with an opportunity to reflect on their counselling of patients using opioids for chronic non-cancer pain, recognise the limited evidence of benefits of opioids, refresh knowledge on the serious harms of long-term use, identify factors that place patients at increased risk of harms and reflect on strategies that have been implemented to promote safe use of opioids.

Pharmacists will have the option to complete the review for 5 episodes of care as an express version, or continue to the standard 10 episodes of care.

Participants receive a counselling checklist and practice tips for starting conversations with patients about opioid tapering. An expert commentary provided by Karalyn Huxhagen, BPharm FPS AACPA is included in the activity.

This Pharmacy Practice Review provides an opportunity for pharmacists to be accredited for up to 8 hours of Group 3 CPD (or 24 CPD points).

Other NPS MedicineWise Pharmacy Practice Reviews cover a wide range of topics, including PPIs, type 2 diabetes, COPD and depression.

Pharmacists can also earn Group 2 CPD credits by participating in other activities such as clinical case studies and online learning courses, including modules on management of infections, medication safety training and adverse event reporting. We also offer a range of on-demand webinars which offer self-recorded CPD for pharmacists.

You may also like Breast cancer drugs; warning of rare but serious lung inflammation


News & Trends - Pharmaceuticals

Federal court dismisses Arrotex dispute against Health Minister

Federal court dismisses Arrotex dispute against Health Minister

Health Industry Hub | July 12, 2024 |

Pharma News: The Federal Court has ruled against Arrotex Pharmaceuticals in their bid to challenge the Minister for Health and […]

More


News & Trends - Pharmaceuticals

Largest diabetes study reveals major benefits of dual therapy with SGLT2 inhibitors and GLP1 receptor agonists

Largest diabetes study reveals major benefits of SGLT2 inhibitors and GLP1 receptor agonists dual therapy

Health Industry Hub | July 12, 2024 |

Pharma News: Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to […]

More


News & Trends - Pharmaceuticals

Queensland opens first regional CAR T-cell treatment centre

Queensland launches first regional CAR T-cell treatment centre

Health Industry Hub | July 12, 2024 |

Pharma News: Gilead Sciences and Lymphoma Australia have welcomed the opening of Australia’s first regional CAR T-cell treatment centre at […]

More


News & Trends - Pharmaceuticals

Government inaction leaves essential medicine shortages unresolved

Government inaction leaves essential medicine shortages unresolved

Health Industry Hub | July 12, 2024 |

Pharma News: Over the past 12 months, at least six essential medications and products have been withdrawn from the Australian […]

More


This content is copyright protected. Please subscribe to gain access.